Lima Mayara Santa Rosa, Lima Vanessa Cristina Oliveira de, Piuvezam Grasiela, Azevedo Kesley Pablo Morais de, Maciel Bruna Leal Lima, Morais Ana Heloneida de Araújo
Biochemistry Postgraduate Program, Biosciences Center.
Collective Health Postgraduate Program (PPGSCoL).
Medicine (Baltimore). 2019 Sep;98(39):e17285. doi: 10.1097/MD.0000000000017285.
Tumor necrosis factor-alpha (TNF-alpha), among cytokines that mediate the inflammatory process, plays an important role in diseases involving the loss of intestinal barrier integrity. Several molecules with anti-TNF-alpha activity have been studied aiming to develop new therapies. The purpose of this paper is to describe the systematic review protocol of experimental studies that determine mechanisms of action of molecules with anti-TNF-alpha activity on intestinal barrier inflammation.
This protocol is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes Protocols (PRISMA-P). The databases to be searched are PubMed, EMBASE, Scopus, ScienceDirect, and Web of Science. Experimental studies in rats or mice that assessed the activity of anti-TNF-alpha molecules in models of intestinal barrier inflammation will be included in the systematic review. Studies characteristics, experimental model, and main results will be described and the bias risk assessment will be performed. Two independent reviewers will perform study selection, data extraction, and methodological quality assessment. A narrative synthesis will be made for the included studies. Also, if sufficient data is available, a meta-analysis will be conducted. I statistics will be used to assess heterogeneity.
The present protocol will assist in producing a systematic review that identifies the mechanisms underlying the reduction of TNF-alpha in intestinal barrier inflammation models.
The systematic review may contribute to the theoretical basis of research on new molecules with anti-TNF-alpha potential and, consequently, in the development of new therapies employed in humans.
CRD42019131862.
在介导炎症过程的细胞因子中，肿瘤坏死因子-α（TNF-α）在涉及肠屏障完整性丧失的疾病中起重要作用。为开发新疗法，已对几种具有抗TNF-α活性的分子进行了研究。本文旨在描述确定具有抗TNF-α活性的分子对肠屏障炎症作用机制的实验研究的系统评价方案。
本方案以系统评价与Meta分析方案的首选报告项目（PRISMA-P）为指导。将检索的数据库有PubMed、EMBASE、Scopus、ScienceDirect和Web of Science。系统评价将纳入评估抗TNF-α分子在肠屏障炎症模型中活性的大鼠或小鼠实验研究。将描述研究特征、实验模型和主要结果，并进行偏倚风险评估。两名独立的评审员将进行研究选择、数据提取和方法学质量评估。将对纳入的研究进行叙述性综合分析。此外，如果有足够的数据，将进行Meta分析。将使用I统计量评估异质性。
本方案将有助于进行一项系统评价，以确定肠屏障炎症模型中TNF-α降低的潜在机制。
该系统评价可能有助于为具有抗TNF-α潜力的新分子的研究提供理论基础，从而有助于开发用于人类的新疗法。
PROSPERO注册号：CRD42019131862。
